Enliven Therapeutics, Inc. (ELVN) earnings
ELVN earnings moved a median of -1.28% by the close. Quarterly and annual ELVN reports and results, each read against the price at its own news timestamp. Back to the ELVN overview →
11 measured ELVN earnings events.
Where these ELVN earnings landedvs 10 measured ELVN earnings reactions
| Middle 50% of ELVN earnings reactions | -2.79% to +4.04% |
|---|---|
| Median reaction (to close) | -1.28% |
| Measured reactions | 10 |
Point-in-time · zero look-ahead
Half of the 10 ELVN earnings events with a measured close landed between -2.79% and +4.04%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Press release | -1.87% | +7.01% | |
| Form 10-Q Enliven Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.87% | +7.01% | |
| Form 10-Q Enliven Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.37% | +1.57% | |
| Form 10-Q Enliven Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.23% | -2.60% | |
| Form 10-K Enliven Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +4.86% | |
| Form 10-Q Enliven Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.61% | — | |
| Form 10-Q Enliven Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.08% | -0.85% | |
| Form 10-Q Enliven Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -5.20% | -8.33% | |
| Form 10-K Enliven Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.42% | -1.71% | |
| Form 10-Q Enliven Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.27% | -5.53% | |
| Form 10-Q Enliven Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.50% | -2.85% |
Keep exploring
More ELVN: analyst actions → · SEC filings → · ELVN overview →